


AMENDMENTS TO THE CLAIMS

1. (Original) A dendrite elongation inhibitor for melanocytes consisting of a compound represented by the following general formula (1):




formula (1)

and/or a salt thereof,

wherein R₁, R₂, R₃, R₄, R₅, and R₆ each independently represent a hydrogen atom or a C₁₋₄ alkyl group.

2. (Currently amended) The dendrite elongation inhibitor for melanocytes according to claim 1, ~~characterized in that~~ wherein the compound represented by the general formula (1) is Centaureidin indicated by the following formula.




3. (Original) A skin preparation for external use for inhibiting elongation of melanocytic dendrites, comprising the dendrite elongation inhibitor for melanocytes according to claim 1 or 2 as an active ingredient.

4. (Currently amended) The skin preparation for external use for inhibiting elongation of melanocytic dendrites according to claim 3, ~~characterized in that~~wherein the skin preparation for external use ~~is used for alleviating~~alleviates dyschromatosis on which tyrosinase inhibitors have insufficient effect.

5. (Currently amended) The skin preparation for external use for inhibiting elongation of melanocytic dendrites according to claim 3[[or 4]], ~~characterized in that~~wherein the skin preparation for external use is a cosmetic.

6. (New) The skin preparation for external use for inhibiting elongation of melanocytic dendrites according to claim 4, wherein the skin preparation for external use is a cosmetic.

7. (New) A method for inhibiting elongation of melanocytic dendrites comprising:
a step of applying a skin preparation for external use for inhibiting elongation of melanocytic dendrites, comprising, as an active ingredient, a dendrite elongation inhibitor for melanocytes consisting of a compound represented by the following general formula (1):




formula (1)

and/or a salt thereof,

wherein R₁, R₂, R₃, R₄, R₅, and R₆ each independently represent a hydrogen atom or a C₁₋₄ alkyl group.

Int'l Appl. No. : PCT/JP03/15267
Int'l filing date : November 28, 2003

8. (New) The method for inhibiting elongation of melanocytic dendrites according to claim 7, wherein the compound represented by the general formula (1) is Centaureidin indicated by the following formula.



9. (New) The method for inhibiting elongation of melanocytic dendrites according to claim 7 or 8, wherein the skin preparation for external use alleviates dyschromatosis on which tyrosinase inhibitors have insufficient effect.

10. (New) The method for inhibiting elongation of melanocytic dendrites according to claim 7 or 8, wherein the skin preparation for external use is a cosmetic.

11. (New) The method for inhibiting elongation of melanocytic dendrites according to claim 9, wherein the skin preparation for external use is a cosmetic.